Syntis Bio, a new company founded by biotech veterans Bob Langer and Giovanni Traverso, has emerged with plans to develop pills for a variety of conditions including obesity and rare diseases. Their technology, called SYNT, coats organ surfaces to change drug absorption or hormone triggers. Inspired by the adhesive used by mussels, this oral polymer chemistry is the core approach of Syntis. The company, founded in 2022 by Langer, Traverso, and CEO Rahul Dhanda, aims to revolutionize drug delivery methods. With a focus on creating innovative solutions, Syntis Bio is set to disrupt the biotech sector.
Source link
Biotech co-founded by Bob Langer is taking on a new approach to obesity
